Literature DB >> 32895312

Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.

Antonella Pietragalla1, Martina Arcieri2, Claudia Marchetti1, Giovanni Scambia3,4, Anna Fagotti1,4.   

Abstract

Several genes associated with hereditary ovarian cancer have been discovered as a result of the work done with next generation sequencing. It is estimated that approximately 23% of ovarian carcinomas have a hereditary predisposition. The most common hereditary condition is represented by germline mutations in BRCA1 or BRCA2 genes that account for 20-25% of high grade serous ovarian cancer. A number of other hereditary ovarian cancers are associated with different genes, with a crucial role in the DNA damage response pathway, such as the mismatch repair genes in Lynch syndrome, TP53 in Li-Fraumeni syndrome, STK11 in Peutz-Jeghers syndrome, CHEK2, RAD51, BRIP1, and PALB2. The goal of this manuscript is to summarize the published data regarding the molecular pathways involved in the pathogenesis of non-BRCA related hereditary ovarian cancer and to provide a tool that might be useful in discussing risk assessment, genetic testing, prevention strategies, as well as clinical and therapeutic implications for patients with ovarian cancer. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  BRCA1 Protein; BRCA2 Protein; homologous recombination; ovarian cancer

Year:  2020        PMID: 32895312     DOI: 10.1136/ijgc-2020-001556

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  13 in total

Review 1.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

Review 2.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

Review 3.  Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.

Authors:  Ying L Liu; Kelsey Breen; Amanda Catchings; Megha Ranganathan; Alicia Latham; Deborah J Goldfrank; Rachel N Grisham; Kara Long Roche; Melissa K Frey; Dennis S Chi; Nadeem Abu-Rustum; Carol Aghajanian; Kenneth Offit; Zsofia K Stadler
Journal:  JCO Oncol Pract       Date:  2021-09-28

4.  ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis.

Authors:  Yanna Zhang; Ting Du; Xiancheng Chen
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 5.  Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).

Authors:  Ling Yang; Hong-Jian Xie; Ying-Ying Li; Xia Wang; Xing-Xin Liu; Jia Mai
Journal:  Oncol Rep       Date:  2022-02-25       Impact factor: 3.906

Review 6.  Rare Hereditary Gynecological Cancer Syndromes.

Authors:  Takafumi Watanabe; Shu Soeda; Yuta Endo; Chikako Okabe; Tetsu Sato; Norihito Kamo; Makiko Ueda; Manabu Kojima; Shigenori Furukawa; Hidekazu Nishigori; Toshifumi Takahashi; Keiya Fujimori
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

7.  Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients.

Authors:  Dimitra Stergiopoulou; Athina Markou; Lydia Giannopoulou; Paul Buderath; Ioanna Balgkouranidou; Nikolaos Xenidis; Stylianos Kakolyris; Sabine Kasimir-Bauer; Evi Lianidou
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

8.  Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.

Authors:  Emily A Goebel; Jennifer Kerkhof; Oleksandra Dzyubak; C Meg McLachlin; Jacob McGee; Bekim Sadikovic
Journal:  Genes (Basel)       Date:  2022-08-06       Impact factor: 4.141

Review 9.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

Review 10.  DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?

Authors:  Dimitra T Stefanou; Vassilis L Souliotis; Roubini Zakopoulou; Michalis Liontos; Aristotelis Bamias
Journal:  Biomedicines       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.